Skip to main content

Table 1 Characteristics of participants according to α1-antitrypsin genotype

From: Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease: a cohort study of 91,540 individuals and a meta-analysis

Genotype

MM

SZ

ZZ

Women/men

50,206/40,942

124/83

95/90

Age, yrs

57.8 ± 13.1

56.7 ± 13.3

54.8 ± 13.1

Body mass index, kg/m2

26.2 ± 4.3

26.3 ± 4.7

26.2 ± 5.2

Plasma α1-antitrypsin, µmol/L

24.0 ± 4.1

10.4 ± 2.0

4.7 ± 4.8

FEV1/FVC, %

77.4 ± 15.9

76.5 ± 10.6

60.3 ± 19.3

Smoking, no. (%)

   

 Never smoker

35,533 (40.6)

84 (42.9)

73 (41.4)

 Ex smoker

36,119 (41.3)

82 (41.6)

89 (51.7)

 Current smoker

15,861 (18.1)

31 (15.8)

12 (6.9)

Chronic Obstructive Pulmonary Disease, no. (%)

5,137 (5.7)

25 (12.2)

100 (54.1)

Antihypertensive medication, no. (%)

17,898 (19.7)

45 (22.0)

41 (22.7)

  1. Values presented as mean ± SD or number (%). P value < 0.01, Pvalue < 0.001 on Student’s t-test or Pearson’s χ2 test versus MM genotype. FEV1 forced expiratory volume in 1 s. FVC forced vital capacity